We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Bispecific Antibody

News List

Oxford BioTherapeutics Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Five Bispecific Antibody Programs for up to $450 Million expressbpd
December 11, 2018
WuXi Biologics and Oxford BioTherapeutics Ltd. announced the expansion of their strategic and innovative immuno-oncology (IO) alliance...
WuXi Biologics Announced Exclusive Discovery Research with Brii Biosciences for Novel Bispecific Antibody Immunotherapeutics en-cphi.cn
December 10, 2018
WuXi Biologics announces a strategic collaboration with Brii Biosciences.
Zymeworks and LEO Pharma Enter into Bispecific Antibody Licensing and Research Collaboration pharmafocusasia
December 04, 2018
Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional therapeutics, and LEO Pharma A/S, a global leader in medical dermatology.....
I-Mab Biopharma Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Three Bispecific Antibody Programs Wuxi Biologics
September 27, 2018
WuXi Biologics and I-Mab Biopharma jointly announce today that I-Mab has expanded strategic collaboration with WuXi Biologics and licensed proprietary WuXiBody™ Platform to develop three bispecific antibodies.

Previous page 1 2 3 Next page